MONECO Advisors LLC Has $498,000 Holdings in Bristol-Myers Squibb (NYSE:BMY)

MONECO Advisors LLC raised its stake in Bristol-Myers Squibb (NYSE:BMY) by 34.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,709 shares of the biopharmaceutical company’s stock after acquiring an additional 2,494 shares during the quarter. MONECO Advisors LLC’s holdings in Bristol-Myers Squibb were worth $498,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Northwest Financial Advisors acquired a new stake in Bristol-Myers Squibb in the 4th quarter valued at about $27,000. Pacific Capital Wealth Advisors Inc. bought a new position in shares of Bristol-Myers Squibb in the 4th quarter valued at about $34,000. VisionPoint Advisory Group LLC boosted its stake in shares of Bristol-Myers Squibb by 300.5% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 737 shares of the biopharmaceutical company’s stock valued at $43,000 after purchasing an additional 553 shares during the last quarter. Turtle Creek Wealth Advisors LLC bought a new position in shares of Bristol-Myers Squibb in the 4th quarter valued at about $40,000. Finally, Wetzel Investment Advisors Inc. bought a new position in shares of Bristol-Myers Squibb in the 4th quarter valued at about $40,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol-Myers Squibb Trading Down 0.6 %

Bristol-Myers Squibb stock opened at $40.97 on Tuesday. Bristol-Myers Squibb has a twelve month low of $39.91 and a twelve month high of $66.38. The company has a current ratio of 1.11, a quick ratio of 0.99 and a debt-to-equity ratio of 2.99. The company has a 50 day moving average of $44.30 and a 200-day moving average of $48.67.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share for the quarter, beating the consensus estimate of ($4.53) by $0.13. The company had revenue of $11.87 billion during the quarter, compared to analysts’ expectations of $11.45 billion. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. The business’s quarterly revenue was up 4.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.05 earnings per share. Equities analysts predict that Bristol-Myers Squibb will post 0.59 EPS for the current year.

Analysts Set New Price Targets

Several brokerages have recently issued reports on BMY. Wells Fargo & Company raised their target price on shares of Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an “equal weight” rating in a research note on Thursday, April 18th. William Blair reaffirmed a “market perform” rating on shares of Bristol-Myers Squibb in a research note on Monday, April 1st. Barclays reduced their target price on shares of Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating on the stock in a research note on Friday, April 26th. BMO Capital Markets reduced their price objective on shares of Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating on the stock in a research note on Friday, April 26th. Finally, StockNews.com lowered shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research note on Monday. One equities research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and four have assigned a buy rating to the company. According to MarketBeat.com, Bristol-Myers Squibb has an average rating of “Hold” and an average price target of $60.00.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.